CMA vs IKT
CMA (CMA) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
CMA (CMA) common stock.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
CMA does not have a complete income-statement cache yet.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
IKT currently screens at market cap $215.2M.
Not investment advice. Open the CMA and IKT stock pages for the full models.
Not investment advice.